CARDIOVASCULAR JOURNAL OF AFRICA • Volume 25, No 6, November/December 2014
294
AFRICA
14. Myers MG. Replacing manual sphygmomanometers with automated
blood pressure measurement in routine clinical practice.
Clin Exp
Pharmacol Physiol
2014;
41
(1): 46–53.
15. Beckett NS, Peters R, Fletcher AE,
et al
. HYVET study group.
Treatment of hypertension in patients 80 years of age or older.
N Engl J
Med
2008;
358
: 2417–2428.
16. Wright JT Jr, Fine LJ, LacklandDT, Ogedegbe G, DennisonHimmelfarb
CR. Evidence supporting a systolic blood pressure goal of less than 150
mmHg in patients aged 60 years or older: the minority view.
Ann Intern
Med
2014;
160
(7): 499–503.
17. South African Dyslipidaemia Guideline Consensus Statement. A joint
statement from the South African Heart Association (SA Heart) and the
Lipid and Atherosclerosis Society of Southern Africa (LASSA)
S Afr
Med J
2012;
102
:177–188.
18. Amod A, Motala A, Levitt N,
et al
.: guideline committee. The 2012
SEMDSA guideline for the management of type 2 diabetes.
J Endocrinol
Metab Diabetes SA
2012;
17
(1): S1–S94.
19. Zanchetti A, Hansson L, Dahlöf B, Julius S, Ménard J, Warnold I,
Wedel H; HOT study group. Benefit and harm of low-dose aspirin in
well-treated hypertensives at different baseline cardiovascular risk.
J
Hypertens
2002;
20
(11): 2301–2307.
20. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM.
Aliskiren and the calcium channel blocker amlodipine combination as
an initial treatment strategy for hypertension control (ACCELERATE):
a randomised, parallel-group trial.
Lancet
2011;
377
: 312–320.
21. Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS.
Initial combination therapy reduces the risk of cardiovascular events in
hypertensive patients: a matched cohort study.
Hypertension
2013;
61
:
309–318.
22. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness
of fixed-dose combinations of antihypertensive agents: a meta-analysis.
Hypertension
2010;
55
: 399–407.
23. Brewster LM, Seedat YK. Why do hypertensive patients of African
ancestry respond better to calcium blockers and diuretics than to ACE
inhibitors and
β
-adrenergic blockers? A systematic review.
BMC Med
2013;
11
: 141.
24. Herbert CJ, Vidt DG. Hypertensive crisis.
Prim Care
2008;
35
: 478–487.
25. Handler J. Hypertensive urgency.
J Clin Hypertens
2006;
8
: 61–64.
26. Neurological Association of South Africa/South African Medical
Association. Stroke therapy guideline.
S Afr Med J
2000;
90
: 276–306.
27. Chapman N, Dobson J, Wilson S,
et al
. Anglo-Scandinavian cardiac
outcomes trial investigators. Effect of spironalactone on blood pressure
in subjects with resistant hypertension.
Hypertension
2007;
49
: 839–845.
28. Chapman N, Chang CL, Dahlöf B, Sever PS, Wedel H, Poulter NR, on
behalf of the ASCOT investigators. Effect of doxazosin gastrointesti-
nal therapeutic system as third-line antihypertensive therapy on blood
pressure and lipids in the Anglo-Scandinavian cardiac outcomes trial.
Circulation
2008;
118
: 42–48.
29. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-
Singh K,
et al
. Percutaneous renal denervation in patients with
treatment-resistant hypertension: final 3-year report of the Symplicity
HTN-1 study.
Lancet
2014;
383
: 622–629.
30. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka
PA; Symplicity HTN-2 investigators. Renal sympathetic denervation
for treatment of drug-resistant hypertension: one-year results from the
Symplicity HTN-2 randomized, controlled trial.
Circulation
2012;
126
:
2976–2982.
31. Bhatt DL, Kandzari DE, O’Neill WW,
et al
. Symplicity HTN-3 investi-
gators. A controlled trial of renal denervation for resistant hypertension.
N Engl J Med
2014;
370
: 1393–1401.
32. Opie LH, Seedat YK. Hypertension in sub-Saharan African popula-
tions.
Circulation
2005;
112
: 3562–3568.
33. Seedat YK. Diabetes mellitus in South African Indians. In: V Mohan
and GHR Rao (eds).
Type 2 Diabetes in South Asians: Epidemiology,
Risk Factors and Prevention.
New Delhi: Jaypee Brothers, 2007: 40–44.
ISBN 81-8061-936-2.
34. Seedat YK. Varying responses to hypotensive agents in different racial
groups, black versus white differences.
J Hypertens
1989;
7
: S15–18.
35. Kostis JB, Kim HJ, Rusnak J,
et al.
Incidence and characteristics of
angioedema associated with enalapril.
Arch Intern Med
2005;
165
:
1637–1642.
36. Sinaiko AR. Hypertension in children.
N Engl J Med
1996;
335
:
1968–1973.
37. Task force on blood pressure control in children. Report of the second
task force on blood pressure control in children, 1987. National Heart,
Lung, and Blood Institute, Bethesda, Maryland.
Pediatrics
1987;
79
:
1–25.
38. Bradshaw D, Steyn K, Levitt N, Nojilana B. Non-communicable diseas-
es – A race against time.
http://www.mrc.ac.za/policybriefs/raceagainst.pdf (accessed 5th May 2014).
39. Wearne N, Swanepoel CR, Boulle A, Duffield MS, Rayner BL. The
spectrum of renal histologies seen in HIV with outcomes, prognostic
indicators, and clinical correlations.
Nephrol Dial Transplant
2012;
27
(11): 4109–4118.
40. Seaberg EC, Munoz A, Lu M,
et al
. Association between highly active
anti-retroviral therapy in a large in a large cohort of men followed from
1984 to 2003. Multicenter AIDS cohort study.
AIDS
2005;
19
: 953–960.
41. Glesby MJ, Aberg JA, Kendall MA, et al. AIDS clinical trials group
A5159 protocol team. Pharmacokinetic interactions between indinavir
plus ritonavir and calcium channel blockers.
Clin Pharmacol Ther
2005;
78
: 143–153.
42. De Maat M, Ekhart GC, Huitema ADR, Koks CH, Mulder JW, Beijnen
JH. Drug interactions between antiretroviral drugs and co-medicated
agents.
Clin Pharmacokinet
2003;
44
: 223–282.